Disease activity is associated with changes in the innate immune function in patients with systemic lupus erythematosus.
Jiram Torres-RuizMarina Rull-GabayetNancy R Mejía-DomínguezDaniel Alberto Carrillo-VázquezJuan Alberto Reyes-IslasFabiola Cassiano-QuezadaJennifer Cuellar-RodríguezJuan Sierra-MaderoJessica Márquez SánchezJesús Salvador Serrano-GarcíaAlexia Esquinca GonzálezGuillermo Juárez-VegaMiguel Tapia-RodríguezDiana Gómez-MartínPublished in: Clinical rheumatology (2023)
Disease activity regulates the innate immune function in SLE which may contribute to the clinical features and infection predisposition. Key points • This is the first cohort study addressing the effect of disease activity and prednisone use on the innate immune function of lupus patients. • Our results show that the disease activity is a key regulator of the respiratory burst, phagocytosis, and the production of neutrophil extracellular traps. • Also, we observed a differential proportion of monocyte subsets according to SLE disease activity. • We consider that our manuscript contributes to the evidence addressing the intrinsic immune abnormalities of patients with SLE regardless of the use of immunosuppressants and set the bases for new research work considering the disease activity as an element to decide the prescription and duration of antibiotic prophylaxis in SLE patients, which is of interest to all rheumatologists.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- innate immune
- rheumatoid arthritis patients
- ankylosing spondylitis
- end stage renal disease
- juvenile idiopathic arthritis
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- ejection fraction
- prognostic factors
- patient reported outcomes
- dendritic cells
- immune response
- peripheral blood